Iterum Therapeutics Files 8-K Report

TL;DR

Iterum Therapeutics filed an 8-K on 6/26/24 for 'Other Events'.

AI Summary

On June 26, 2024, Iterum Therapeutics plc filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events are detailed in the provided excerpt, suggesting a routine or administrative filing.

Why It Matters

This filing signals a disclosure event for Iterum Therapeutics, though the specific nature of the 'Other Events' requires further investigation into the full document.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently poses a high risk.

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• June 26, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
• $1.21 — ts ("Units") at a subscription price of $1.21 per whole unit (the "Rights Offering").
• $0.605 — 0.50 Units, at a subscription price of $0.605 per 0.50 Units (the "Subscription Price

Filing Documents

• itrm-20240626.htm (8-K) — 48KB
• 0000950170-24-077963.txt ( ) — 166KB
• itrm-20240626.xsd (EX-101.SCH) — 26KB
• itrm-20240626_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On June 26, 2024, Iterum Therapeutics plc (the "Company") announced that it has fixed the close of business (5:00 p.m., Eastern Time) on July 16, 2024, as the record date (the "Record Date") for its proposed rights offering. As previously disclosed, the Company plans to distribute subscription rights to the Company's shareholders and holders of warrants that have contractual rights to participate in this offering, which have not been waived (each, an "eligible warrant" and collectively, the "eligible warrants") as of the Record Date, non-transferable subscription rights to purchase an aggregate of 8,503,800 units ("Units") at a subscription price of $1.21 per whole unit (the "Rights Offering"). As of the date hereof, one holder of eligible warrants to purchase 56,606 ordinary shares has waived their contractual right to participate in the Rights Offering. Each shareholder and holder of eligible warrants will receive one subscription right for every ordinary share owned and every ordinary share issuable upon exercise of eligible warrants at 5:00 p.m., Eastern Time on the Record Date. Each whole Unit will consist of (a) one ordinary share, (b) a warrant to purchase 0.5 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (the "1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (the "5-year warrants" and, together with the 1-year warrants, the "warrants") which we refer to as the "basic subscription right." Each subscription right will entitle its holder to purchase 0.50 Units, at a subscription price of $0.605 per 0.50 Units (the "Subscription Price" and such subscription right, the "Basic Subscription Right"), consisting of (a) 0.50 ordinary shares (b) a 1-year warrant to purchase 0

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: June 26, 2024 By: /s/ Corey N. Fishman Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR